| $385M | ||
| $350M | ||
| $215M | ||
| $94M | ||
| $82M | ||
| $62M |
Buys | $256,050 | 1 | 10 |
Sells | $183,167 | 9 | 90 |
| Luly Jay R. | President and CEO | 1 | $256,050 | 1 | $67,493 | $188,557 |
| Capps Kathleen S. | See Remarks | 0 | $0 | 2 | $7,486 | $-7,486 |
| Rottinghaus Scott T. | Chief Medical Officer | 0 | $0 | 1 | $11,356 | $-11,356 |
| Trout Harry R. III | See Remarks | 0 | $0 | 2 | $13,017 | $-13,017 |
| Luu Brendan | Chief Business Officer | 0 | $0 | 1 | $19,837 | $-19,837 |
| Kieffer Tara Lynn | Chief Product Strategy Officer | 0 | $0 | 1 | $29,968 | $-29,968 |
| Or Yat Sun | Chief Scientific Officer | 0 | $0 | 1 | $34,010 | $-34,010 |
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. Enanta Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Watertown, Massachusetts.
Over the last 12 months, insiders at Enanta Pharmaceuticals, Inc. have bought $256,050 and sold $183,167 worth of Enanta Pharmaceuticals, Inc. stock.
On average, over the past 5 years, insiders at Enanta Pharmaceuticals, Inc. have bought $256,050 and sold $2.66M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Luly Jay R. (President and CEO) — $256,050.
The last purchase of 45,000 shares for transaction amount of $256,050 was made by Luly Jay R. (President and CEO) on 2025‑02‑12.
| 2025-12-05 | Sale | Luly Jay R. | President and CEO | 4,743 0.0217% | $14.23 | $67,493 | -2.64% | |
| 2025-12-05 | Sale | Or Yat Sun | Chief Scientific Officer | 2,390 0.0109% | $14.23 | $34,010 | -2.64% | |
| 2025-12-05 | Sale | Luu Brendan | Chief Business Officer | 1,394 0.0064% | $14.23 | $19,837 | -2.64% | |
| 2025-12-05 | Sale | Kieffer Tara Lynn | Chief Product Strategy Officer | 2,106 0.0096% | $14.23 | $29,968 | -2.64% | |
| 2025-12-05 | Sale | Rottinghaus Scott T. | Chief Medical Officer | 798 0.0036% | $14.23 | $11,356 | -2.64% | |
| 2025-12-05 | Sale | Trout Harry R. III | See Remarks | 542 0.0025% | $14.23 | $7,713 | -2.64% | |
| 2025-12-05 | Sale | Capps Kathleen S. | See Remarks | 323 0.0015% | $14.23 | $4,596 | -2.64% | |
| 2025-12-02 | Sale | Trout Harry R. III | See Remarks | 380 0.0018% | $13.96 | $5,305 | +2.01% | |
| 2025-12-02 | Sale | Capps Kathleen S. | See Remarks | 207 0.001% | $13.96 | $2,890 | +2.01% | |
| 2025-02-12 | Luly Jay R. | President and CEO | 45,000 0.2147% | $5.69 | $256,050 | +32.25% | ||
| 2024-12-06 | Sale | Luly Jay R. | President and CEO | 5,142 0.0244% | $8.06 | $41,445 | -9.63% | |
| 2024-12-06 | Sale | Or Yat Sun | Chief Scientific Officer | 2,591 0.0123% | $8.06 | $20,883 | -9.63% | |
| 2024-12-06 | Sale | MELLETT PAUL J | Chief Fin. & Admin Officer | 2,591 0.0123% | $8.06 | $20,883 | -9.63% | |
| 2024-12-06 | Sale | Luu Brendan | Chief Business Officer | 2,283 0.0108% | $8.06 | $18,401 | -9.63% | |
| 2024-12-06 | Sale | Kieffer Tara Lynn | Chief Product Strategy Officer | 2,283 0.0108% | $8.06 | $18,401 | -9.63% | |
| 2024-12-06 | Sale | Rottinghaus Scott T. | Chief Medical Officer | 866 0.0041% | $8.06 | $6,980 | -9.63% | |
| 2024-07-15 | Sale | Rottinghaus Scott T. | Chief Medical Officer | 5,375 0.0355% | $17.08 | $91,805 | -54.69% | |
| 2024-07-12 | Sale | Rottinghaus Scott T. | Chief Medical Officer | 2,271 0.0132% | $15.04 | $34,156 | -53.13% | |
| 2024-07-11 | Sale | Rottinghaus Scott T. | Chief Medical Officer | 4,299 0.0251% | $15.07 | $64,786 | -49.97% | |
| 2024-06-17 | Sale | Kieffer Tara Lynn | Chief Product Strategy Officer | 7,266 0.0315% | $12.33 | $89,590 | -33.22% |
| Luly Jay R. | President and CEO | 858026 4.0219% | $11.19M | 1 | 19 | |
| Or Yat Sun | Chief Scientific Officer | 371392 1.7409% | $4.84M | 0 | 20 | |
| Luu Brendan | Chief Business Officer | 38329 0.1797% | $499,810.16 | 0 | 3 | |
| Kieffer Tara Lynn | Chief Product Strategy Officer | 30620 0.1435% | $399,284.80 | 0 | 4 | |
| Rottinghaus Scott T. | Chief Medical Officer | 21792 0.1021% | $284,167.68 | 0 | 6 | |
| Trout Harry R. III | See Remarks | 16348 0.0766% | $213,177.92 | 0 | 2 | |
| Capps Kathleen S. | See Remarks | 8377 0.0393% | $109,236.08 | 0 | 2 | |
| Goldberg Marc E. | director | 547606 2.5669% | $7.14M | 0 | 3 | |
| SCHUHSLER HELMUT | 380487 1.7835% | $4.96M | 1 | 3 | +19.31% | |
| TVM V LIFE SCIENCE VENTURES GMBH & CO KG | 10 percent owner | 276999 1.2984% | $3.61M | 1 | 7 | +19.31% |
| MELLETT PAUL J | Chief Fin. & Admin Officer | 91710 0.4299% | $1.2M | 0 | 21 | |
| Gardiner Nathaniel S. | Sr. VP & General Counsel | 68154 0.3195% | $888,728.16 | 3 | 2 | +9.2% |
| Adda Nathalie | Sr. VP & Chief Medical Officer | 47191 0.2212% | $615,370.64 | 0 | 14 | |
| AFTING ERNST-GUENTER | director | 17287 0.081% | $225,422.48 | 0 | 1 | |
| SAINTS CAPITAL GRANITE, L.P. | 10 percent owner | 16904 0.0792% | $220,428.16 | 1 | 8 | +19.31% |
| Ocain Tim | Senior Vice President | 6127 0.0287% | $79,896.08 | 0 | 1 | |
| Vance Terry | director | 5800 0.0272% | $75,632.00 | 2 | 1 | +8.96% |
| CARTER BRUCE L A | 3324 0.0156% | $43,344.96 | 0 | 4 | ||
| Verdine Gregory L. | director | 3324 0.0156% | $43,344.96 | 1 | 0 | +19.31% |
| Buckley Stephen Jr. | director | 2000 0.0094% | $26,080.00 | 3 | 0 | +6.42% |
| Golumbeski George | director | 0 0% | $0 | 0 | 3 |
$87,639,490 | 62 | 18.37% | $312.24M | |
$109,415,500 | 33 | 18.13% | $224.27M | |
$64,487,106 | 32 | -22.92% | $261.45M | |
$79,019,806 | 27 | 7.24% | $315.83M | |
$22,017,898 | 24 | 39.19% | $241.19M | |
$3,668,031 | 23 | 2.05% | $279.63M | |
$1,842,003 | 22 | -0.74% | $286M | |
$6,915,275 | 21 | -32.61% | $238.87M | |
Enanta Pharmaceuticals, Inc. (ENTA) | $10,143,329 | 12 | 11.84% | $278.19M |
$170,425 | 10 | -16.01% | $228.12M | |
$145,296,407 | 8 | -0.98% | $222.4M | |
$13,043,783 | 8 | 732.82% | $306.12M | |
$272,982 | 6 | -28.53% | $298.11M | |
$2,720,023 | 3 | -11.76% | $283.62M | |
$37,067 | 3 | -89.81% | $284.6M | |
$16,003,671 | 3 | 55.38% | $248.99M | |
$193,101 | 3 | -25.20% | $247.37M | |
$136,410 | 2 | -13.40% | $321.88M | |
$802,500 | 1 | 5.37% | $267.82M |
| Increased Positions | 56 | +43.75% | 3M | +17.73% |
| Decreased Positions | 53 | -41.41% | 3M | -14.69% |
| New Positions | 25 | New | 1M | New |
| Sold Out Positions | 12 | Sold Out | 514,667 | Sold Out |
| Total Postitions | 131 | +2.34% | 19M | +3.03% |
| Farallon Capital Management Llc | $30,603.00 | 7.32% | 2.12M | 0 | 0% | 2025-09-30 |
| Krensavage Asset Management, Llc | $30,490.00 | 7.29% | 2.11M | 0 | 0% | 2025-09-30 |
| Janus Henderson Group Plc | $28,075.00 | 6.71% | 1.95M | +1M | +271.73% | 2025-09-30 |
| Vanguard Group Inc | $27,958.00 | 6.69% | 1.94M | -37,843 | -1.91% | 2025-09-30 |
| Blackrock, Inc. | $26,432.00 | 6.32% | 1.83M | -13,925 | -0.75% | 2025-09-30 |
| Millennium Management Llc | $13,671.00 | 3.27% | 948,084 | -510,509 | -35% | 2025-09-30 |
| Acadian Asset Management Llc | $12,503.00 | 2.99% | 867,037 | 0 | 0% | 2025-09-30 |
| Commodore Capital Lp | $11,536.00 | 2.76% | 800,000 | +800,000 | New | 2025-09-30 |
| Geode Capital Management, Llc | $7,112.00 | 1.7% | 493,194 | +7,397 | +1.52% | 2025-09-30 |
| Renaissance Technologies Llc | $6,916.00 | 1.65% | 479,600 | +10,100 | +2.15% | 2025-09-30 |